Medinix Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
- Paid Up Capital ₹ 0.50 M
- Company Age 3 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 2240.49%
- Profit Growth 56.97%
- Ebitda 47.45%
- Net Worth -12.30%
- Total Assets 185.54%
About Medinix Pharmaceutical
Medinix Pharmaceutical Private Limited (MPPL) is a Private Limited Indian Non-Government Company incorporated in India on 08 October 2021 (Three years and four months 19 days old ). Its registered office is in Lucknow, Uttar Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 0.50 M, as per Ministry of Corporate Affairs (MCA) records.
Neeraj Kumar and Rohit Kumar serve as directors at the Company.
Company Details
- Location
Lucknow, Uttar Pradesh, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U51909UP2021PTC153598
- Company No.
153598
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Oct 2021
- Date of AGM
05 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Who are the key members and board of directors at Medinix Pharmaceutical?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Neeraj Kumar  | Director | 08-Oct-2021 | Current |
| Rohit Kumar | Director | 08-Oct-2021 | Current |
Financial Performance of Medinix Pharmaceutical.
Medinix Pharmaceutical Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 2240.49% increase. The company also saw a substantial improvement in profitability, with a 56.97% increase in profit. The company's net worth observed a substantial decline by a decrease of 12.3%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Medinix Pharmaceutical?
Unlock access to Medinix Pharmaceutical's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Medinix Pharmaceutical?
Unlock and access historical data on people associated with Medinix Pharmaceutical, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Medinix Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Medinix Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.